AKARI THERAPEUTICS PLC-ADR(NASDAQ:AKTX) stock News

AKTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: OMER SSKN EYPT GNPX ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

8 days ago - By: Akari Therapeutics Plc

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

14 days ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

23 days ago - By: Benzinga - Mentions: QURE AYTU SSKN CLPT ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

10 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Key Leadership Appointments

23 days ago - By: Akari Therapeutics Plc

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

2 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

3 months ago - By: ACCESS Newswire - Mentions: AMIX CNSP NVNO GRI ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

4 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

5 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

5 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

5 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

6 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

6 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

7 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

8 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

9 months ago - By: Akari Therapeutics Plc